BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31366526)

  • 21. Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
    Takimoto Y; Tanabe O; Kuramoto A; Sasaki N; Nanba K
    Acta Haematol; 1994; 92(2):97-100. PubMed ID: 7817711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
    Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
    Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myeloid leukemia as a secondary malignancy after lymphoma in a child. A case report and review of the literature.
    Zahra K; Ben Fredj W; Ben Youssef Y; Zaghouani H; Chebchoub I; Zaier M; Badreddine S; Braham N; Sennana H; Khelif A
    Onkologie; 2012; 35(11):690-3. PubMed ID: 23147546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal dominance and clonal evolution in a patient with a "chronic myeloid neoplasm": a challenge in management.
    Burgstaller S; Webersinke G; Thaler J
    Leuk Lymphoma; 2015 Jan; 56(1):239-41. PubMed ID: 24766465
    [No Abstract]   [Full Text] [Related]  

  • 28. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells.
    Li QF; Huang WR; Duan HF; Wang H; Wu CT; Wang LS
    Oncogene; 2007 Dec; 26(57):7904-8. PubMed ID: 17599053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
    Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
    Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia.
    Costello R; Sainty D; Lafage-Pochitaloff M; Gabert J
    Leuk Lymphoma; 1997 Apr; 25(3-4):225-32. PubMed ID: 9168433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
    Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
    Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
    Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
    Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
    Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
    Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
    Nadarajan VS; Ang CH; Bee PC
    Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
    Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman JU; Kurzrock R
    Leukemia; 1991 Mar; 5(3):191-5. PubMed ID: 2013978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.
    Curi DA; Beauchamp EM; Blyth GT; Arslan AD; Donato NJ; Giles FJ; Altman JK; Platanias LC
    Oncotarget; 2015 Oct; 6(32):33206-16. PubMed ID: 26375673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL).
    Ohsaka A; Shiina S; Kobayashi M; Kudo H; Kawaguchi R
    Intern Med; 2002 Dec; 41(12):1183-7. PubMed ID: 12521212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.